Pancreatic Adenosquamous Carcinoma
NCI Definition: A carcinoma that arises from the pancreas showing both ductal and squamous differentiation. The squamous component should represent at least 30% of the malignant cellular infiltrate. The prognosis is usually worse than that of ductal adenocarcinoma. 
Pancreatic adenosquamous carcinomas most frequently harbor alterations in KRAS, TP53, CDKN2A, SMAD4, and CDKN2B .
KRAS Mutation, KRAS Exon 2 Mutation, KRAS Codon 12 Missense, TP53 Mutation, and KRAS G12D are the most common alterations in pancreatic adenosquamous carcinoma .
There is 1 clinical trial for pancreatic adenosquamous carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains pancreatic adenosquamous carcinoma as an inclusion criterion, 1 is phase 2 (1 open).
Mga012 is the most common intervention in pancreatic adenosquamous carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.